GI Pathology
    ZR392 Rabbit Monoclonal

    Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF-β family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the DPC4 that is always deleted in pancreatic carcinoma, locus 4, also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in various cancers. The lack of SMAD4 expression is present in approximately 80% of cases of pancreatic adenocarcinoma but rarely in endometrial (0%), colorectal (0%), ovarian (3%), lung (0%), breast (2%), adenocarcinomas, and malignant melanoma (4%). SMAD4is an essential marker for confirming a diagnosis of pancreatic adenocarcinoma.

    Species Reactivity:Humans; others not tested
    Known Applications:Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
    Supplied As:Buffer with protein carrier and preservative
    Storage:Store at 2ºC to 8ºC
    Control:Pancreatic adenocarcinoma
    Visualization:Cytoplasmic in absence of ligand. Migrates to nucleus when complexed with R-SMAD.
    Immunogen:Recombinant fragment (around aa400-552) of human SMAD4 protein (exact sequence is proprietary)
    Ordering Information
    Classification IVD
    Catalogue Number Z2748RL
    Classification IVD
    Catalogue Number Z2748RL
    Package Inserts
    IFU-DPC4 (SMAD4) ZR392
    Regulatory Notice
    Product classification varies based on regulations of individual countries. Please contact your local distributor for more information. Products labeled as ASR or RUO in the US might be available as IVD or RUO in respective countries.